175 related articles for article (PubMed ID: 19546052)
1. Molecularly targeted therapies for thyroid cancers.
Sherman SI
Endocr Pract; 2009; 15(6):605-11. PubMed ID: 19546052
[TBL] [Abstract][Full Text] [Related]
2. Targeting RET for thyroid cancer therapy.
Lanzi C; Cassinelli G; Nicolini V; Zunino F
Biochem Pharmacol; 2009 Feb; 77(3):297-309. PubMed ID: 19028457
[TBL] [Abstract][Full Text] [Related]
3. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Roskoski R; Sadeghi-Nejad A
Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
[TBL] [Abstract][Full Text] [Related]
4. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers.
Sherman SI
J Clin Endocrinol Metab; 2009 May; 94(5):1493-9. PubMed ID: 19258410
[TBL] [Abstract][Full Text] [Related]
5. New molecular targeted therapies in thyroid cancer.
Milano A; Chiofalo MG; Basile M; Salzano de Luna A; Pezzullo L; Caponigro F
Anticancer Drugs; 2006 Sep; 17(8):869-79. PubMed ID: 16940797
[TBL] [Abstract][Full Text] [Related]
6. Emerging therapies for thyroid carcinoma.
Walsh S; Prichard R; Hill AD
Surgeon; 2012 Feb; 10(1):53-8. PubMed ID: 22233555
[TBL] [Abstract][Full Text] [Related]
7. Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer.
Sherman SI
Oral Oncol; 2013 Jul; 49(7):707-10. PubMed ID: 23582411
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of sunitinib in the treatment of advanced epithelial thyroid cancer: our experience and review of literature.
Pasqualetti G; Ricci S; Dardano A; Ferdeghini M; Del Tacca M; Monzani F
Mini Rev Med Chem; 2011 Aug; 11(9):746-52. PubMed ID: 21707530
[TBL] [Abstract][Full Text] [Related]
9. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy for thyroid cancer: An updated review of investigational agents.
Deshpande HA; Gettinger SN; Sosa JA
Curr Opin Investig Drugs; 2010 Jun; 11(6):661-8. PubMed ID: 20496261
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy of thyroid cancer.
Sherman SI
Biochem Pharmacol; 2010 Sep; 80(5):592-601. PubMed ID: 20471374
[TBL] [Abstract][Full Text] [Related]
12. The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies.
Lirov R; Worden FP; Cohen MS
Drugs; 2017 May; 77(7):733-745. PubMed ID: 28361210
[TBL] [Abstract][Full Text] [Related]
13. The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.
De Falco V; Carlomagno F; Li HY; Santoro M
Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):307-318. PubMed ID: 28911727
[TBL] [Abstract][Full Text] [Related]
14. New therapies for dedifferentiated papillary thyroid cancer.
Fallahi P; Mazzi V; Vita R; Ferrari SM; Materazzi G; Galleri D; Benvenga S; Miccoli P; Antonelli A
Int J Mol Sci; 2015 Mar; 16(3):6153-82. PubMed ID: 25789503
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib: first global approval.
Scott LJ
Drugs; 2015 Apr; 75(5):553-60. PubMed ID: 25795101
[TBL] [Abstract][Full Text] [Related]
16. [Refractory thyroid cancers].
Schlumberger M; Chougnet C; Baudin E; Leboulleux S;
Presse Med; 2011 Dec; 40(12 Pt 1):1189-98. PubMed ID: 22078085
[TBL] [Abstract][Full Text] [Related]
17. Update on thyroid cancer treatment.
Regalbuto C; Frasca F; Pellegriti G; Malandrino P; Marturano I; Di Carlo I; Pezzino V
Future Oncol; 2012 Oct; 8(10):1331-48. PubMed ID: 23130931
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy for endocrine cancer: the medullary thyroid carcinoma paradigm.
Ye L; Santarpia L; Gagel RF
Endocr Pract; 2009; 15(6):597-604. PubMed ID: 19546050
[TBL] [Abstract][Full Text] [Related]
19. Molecular targeted therapies for patients with refractory thyroid cancer.
Chougnet C; Brassard M; Leboulleux S; Baudin E; Schlumberger M
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):448-55. PubMed ID: 20554167
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological and clinical profile of lenvatinib (E-7080) in the treatment of advanced, radioiodine-refractory, differentiated thyroid cancer.
Hegazi M; Azadi A; Jain D; Redman R; Perez CA
Drugs Today (Barc); 2015 Dec; 51(12):689-94. PubMed ID: 26798849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
